Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
GeneDx (WGS) appointed Everett Cunningham as CEO and board member, effective on or before December 15, 2026. Katherine Stueland will step down from both roles when Cunningham joins and will remain an adviser through January 31, 2027 to support the transition.
Cunningham most recently served as president and CEO of Quanterix. Mark Gardner will remain GeneDx president and report to Cunningham. GeneDx also reaffirmed its full-year 2026 financial guidance, originally provided on November 9, 2026, with its third-quarter results.
Arvinas (Nasdaq: ARVN) announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026.
The chat is scheduled for 9:00 a.m. GMT/4:00 a.m. EST. A live audio webcast will be available under “Events and Presentations” in the Investors and Media section of the company’s website.
Arvinas (Nasdaq: ARVN) will present preliminary Phase 1 data for ARV-393 (zaloblideg) at ASH on December 14, 2026.
The poster will cover early dose-escalation groups receiving ARV-393 alone for relapsed or refractory non-Hodgkin lymphoma, meaning disease that returned or resisted treatment. Planned data include safety, pharmacokinetics—how the body processes the drug—and pharmacodynamics—its effects in the body—from all patients, with preliminary efficacy data from patients with T-cell lymphomas. ARV-393 is an investigational oral drug designed to degrade the BCL6 protein. The presentation is scheduled for 6:00–8:00 p.m. CT at the American Society of Hematology annual meeting in New Orleans.
Arvinas (ARVN) reported third-quarter 2026 revenue of $0.5 million and advanced clinical trials across its investigational protein-degrader portfolio. Revenue fell from $41.9 million a year earlier. GAAP research and development expenses declined to $46.9 million from $64.7 million; general and administrative expenses fell to $12.6 million from $21.0 million.
Cash, cash equivalents, restricted cash and marketable securities totaled $558.9 million at September 30, down from $685.4 million at year-end 2025. Arvinas expects funding to last into the second half of 2028. Patient dosing began in the ARV-6723 Phase 1/2 trial. The company plans ARV-393 data in Q4 2026 and further readouts across three programs in 2027. ARV-102 Parkinson’s data showed improved eye movement correlated with biomarker changes. Its planned 2027 European Union and UK trial in progressive supranuclear palsy requires regulatory authorization; the U.S. application remains on hold.
Arvinas (ARVN) announced the return of its Early Career Researcher Award, offering $25,000 to recognize research in targeted protein degradation. The award recognizes an emerging researcher or research team and will be presented for the second time, with the winner to be formally recognized in mid-2027.
Nominations open November 1, 2026, and must arrive by December 31, 2026, at 11:59 p.m. ET. Eligible researchers must have been in academia at the graduate or postdoctoral level when the studies were conducted and/or published. Self-nominations and joint applications are permitted. Evaluation will consider contributions to innovation in targeted protein degradation, including discoveries, scientific leadership and new approaches.
Arvinas (ARVN) will review third quarter 2026 financial results and provide a corporate update during a webcast on November 3, 2026. The live webcast begins at 8:00 a.m. ET and will be accessible through “Events and Presentations” on the company’s investor page. A replay will be available on the Arvinas website after the event.
Arvinas (Nasdaq: ARVN) presented final Phase 1 data showing exploratory eye-movement improvements with investigational ARV-102 in patients with Parkinson’s disease. The trial evaluated oral doses of 20 mg to 80 mg and placebo for 28 days in 24 patients. Dose-dependent increases in eye-movement amplitude compared with placebo reflected less severe hypometria, or movements falling short of their target.
Biomarkers linked to cellular waste processing and neuroinflammation decreased, while markers of synaptic integrity and axonal guidance increased. Reductions in cerebrospinal fluid LRRK2 protein were associated with improved eye-movement function and changes in these pathway biomarkers. The study was not designed to assess clinical efficacy. Arvinas said the findings support further clinical evaluation of ARV-102. Final results were presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul.
Arvinas (ARVN) will present Phase 1 ARV-102 biomarker data at the International Congress of Parkinson’s Disease and Movement Disorders on October 7, 2026. The data concern participants with Parkinson’s disease and will be shared in a late-breaking oral presentation and an online e-poster. The presentation, titled “Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data,” covers eye-movement and biomarker data. The congress takes place October 4–8, 2026, in Seoul, Korea.
ARV-102 is an investigational oral drug designed to cross the blood-brain barrier and degrade LRRK2, a protein implicated in Parkinson’s disease and progressive supranuclear palsy. It has been evaluated in Phase 1 trials in healthy volunteers and patients with Parkinson’s disease. The announcement schedules the presentations rather than reporting their clinical findings.
Arvinas (Nasdaq: ARVN) granted equity inducement awards to one newly hired employee, effective September 28, 2026.
The awards comprise an option to purchase 64,766 common shares and 42,388 restricted stock units. The option has a 10-year term and an exercise price of $7.51 per share, equal to the stock’s closing price on the grant date. Both awards vest over four years, subject to continued service as an employee or other service provider through the applicable vesting dates. They were granted under Nasdaq Listing Rule 5635(c)(4), outside Arvinas’ stock incentive plan.
Arvinas (ARVN) has dosed the first patient in a Phase 1/2 trial of its immuno-oncology candidate ARV-6723.
The oral drug is designed to degrade HPK1, a protein that restrains immune activation. The global, multicenter ARV-6723-101 study will assess safety, how the drug moves through and affects the body, and preliminary antitumor activity in adults with advanced solid tumors. It begins with ARV-6723 alone and will later assess a combination with pembrolizumab. The initial group is enrolling patients previously treated with an immune checkpoint inhibitor who have no suitable standard treatment options.
In preclinical studies, ARV-6723 showed selective HPK1 degradation, enhanced immune activity and antitumor activity alone and with an immune checkpoint inhibitor. In seven models, it showed single-agent activity where neither an HPK1 inhibitor nor anti-PD-1 therapy showed benefit. Whether HPK1 degradation produces antitumor effects in patients remains to be tested.